Cargando…

Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors

Natural products based on imidazole scaffolds have inspired the discovery of a wide variety of bioactive compounds. Herein, a series of imidazoles that act as competitive and potent cruzain inhibitors was investigated using a combination of ligand- and structure-based drug design strategies. Quantit...

Descripción completa

Detalles Bibliográficos
Autores principales: Medeiros, Alex R., Ferreira, Leonardo L. G., de Souza, Mariana L., de Oliveira Rezende Junior, Celso, Espinoza-Chávez, Rocío Marisol, Dias, Luiz Carlos, Andricopulo, Adriano D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071344/
https://www.ncbi.nlm.nih.gov/pubmed/33920961
http://dx.doi.org/10.3390/biom11040579
_version_ 1783683678728093696
author Medeiros, Alex R.
Ferreira, Leonardo L. G.
de Souza, Mariana L.
de Oliveira Rezende Junior, Celso
Espinoza-Chávez, Rocío Marisol
Dias, Luiz Carlos
Andricopulo, Adriano D.
author_facet Medeiros, Alex R.
Ferreira, Leonardo L. G.
de Souza, Mariana L.
de Oliveira Rezende Junior, Celso
Espinoza-Chávez, Rocío Marisol
Dias, Luiz Carlos
Andricopulo, Adriano D.
author_sort Medeiros, Alex R.
collection PubMed
description Natural products based on imidazole scaffolds have inspired the discovery of a wide variety of bioactive compounds. Herein, a series of imidazoles that act as competitive and potent cruzain inhibitors was investigated using a combination of ligand- and structure-based drug design strategies. Quantitative structure–activity relationships (QSARs) were generated along with the investigation of enzyme–inhibitor molecular interactions. Predictive hologram QSAR (HQSAR, r(2)(pred) = 0.80) and AutoQSAR (q(2) = 0.90) models were built, and key structural properties that underpin cruzain inhibition were identified. Moreover, comparative molecular field analysis (CoMFA, r(2)(pred) = 0.81) and comparative molecular similarity indices analysis (CoMSIA, r(2)(pred) = 0.73) revealed 3D molecular features that strongly affect the activity of the inhibitors. These findings were examined along with molecular docking studies and were highly compatible with the intermolecular contacts that take place between cruzain and the inhibitors. The results gathered herein revealed the main factors that determine the activity of the imidazoles studied and provide novel knowledge for the design of improved cruzain inhibitors.
format Online
Article
Text
id pubmed-8071344
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80713442021-04-26 Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors Medeiros, Alex R. Ferreira, Leonardo L. G. de Souza, Mariana L. de Oliveira Rezende Junior, Celso Espinoza-Chávez, Rocío Marisol Dias, Luiz Carlos Andricopulo, Adriano D. Biomolecules Article Natural products based on imidazole scaffolds have inspired the discovery of a wide variety of bioactive compounds. Herein, a series of imidazoles that act as competitive and potent cruzain inhibitors was investigated using a combination of ligand- and structure-based drug design strategies. Quantitative structure–activity relationships (QSARs) were generated along with the investigation of enzyme–inhibitor molecular interactions. Predictive hologram QSAR (HQSAR, r(2)(pred) = 0.80) and AutoQSAR (q(2) = 0.90) models were built, and key structural properties that underpin cruzain inhibition were identified. Moreover, comparative molecular field analysis (CoMFA, r(2)(pred) = 0.81) and comparative molecular similarity indices analysis (CoMSIA, r(2)(pred) = 0.73) revealed 3D molecular features that strongly affect the activity of the inhibitors. These findings were examined along with molecular docking studies and were highly compatible with the intermolecular contacts that take place between cruzain and the inhibitors. The results gathered herein revealed the main factors that determine the activity of the imidazoles studied and provide novel knowledge for the design of improved cruzain inhibitors. MDPI 2021-04-15 /pmc/articles/PMC8071344/ /pubmed/33920961 http://dx.doi.org/10.3390/biom11040579 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Medeiros, Alex R.
Ferreira, Leonardo L. G.
de Souza, Mariana L.
de Oliveira Rezende Junior, Celso
Espinoza-Chávez, Rocío Marisol
Dias, Luiz Carlos
Andricopulo, Adriano D.
Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors
title Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors
title_full Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors
title_fullStr Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors
title_full_unstemmed Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors
title_short Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors
title_sort chemoinformatics studies on a series of imidazoles as cruzain inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071344/
https://www.ncbi.nlm.nih.gov/pubmed/33920961
http://dx.doi.org/10.3390/biom11040579
work_keys_str_mv AT medeirosalexr chemoinformaticsstudiesonaseriesofimidazolesascruzaininhibitors
AT ferreiraleonardolg chemoinformaticsstudiesonaseriesofimidazolesascruzaininhibitors
AT desouzamarianal chemoinformaticsstudiesonaseriesofimidazolesascruzaininhibitors
AT deoliveirarezendejuniorcelso chemoinformaticsstudiesonaseriesofimidazolesascruzaininhibitors
AT espinozachavezrociomarisol chemoinformaticsstudiesonaseriesofimidazolesascruzaininhibitors
AT diasluizcarlos chemoinformaticsstudiesonaseriesofimidazolesascruzaininhibitors
AT andricopuloadrianod chemoinformaticsstudiesonaseriesofimidazolesascruzaininhibitors